Jan Erik Myklebust • 1971 • Ørsta • 3 roles • 20 shareholdings

Roles

Name	Role	Total operating income	Total equity	Shares
M MYKLE HOLDING AS	Managing Director/CEO	-	-62,097	100 % directly

Name	Role	Total operating income	Total equity	Shares
M MYKLE HOLDING AS	Chairman	-	-62,097	100 % directly
M MYKLEBUST BRANNSIKRING AS	Chairman	4,701,930	616,431	100 % indirectly

Last update: Apr 13, 2023

No related industries

Name	Share class	Total operating income	Total equity	Share
M MYKLE HOLDING AS	Ordinære aksjer	0	-62,097	100 % directly
M MYKLEBUST BRANNSIKRING AS		4,701,930	616,431	100 % indirectly
T TREDET AS	Ordinære aksjer	5,175,874	-134,000	2.38 % directly
I INSR ASA	Ordinære aksjer	42,664,675	158,701,456	0.03 % directly < 0.01 %
Q QUESTLINE AS	Ordinære aksjer	250,000	-154,384	0.02 % directly < 0.01 %
A AKER CARBON CAPTURE ASA Closed	NO0010890304	6,000,000	4,841,000,000	< 0.01 % directly
H HAVILA SHIPPING ASA	Ordinære aksjer	293,303,000	194,673,000	< 0.01 % directly
H HUDDLY AS	Ordinære aksjer	217,403,000	305,854,000	< 0.01 % directly
A AKER HORIZONS ASA Closed	Ordinære aksjer	0	4,048,000,000	< 0.01 % directly
K KONGSBERG AUTOMOTIVE ASA	Ordinære aksjer	8,900,000	267,700,000	< 0.01 % directly
S SOLSTAD OFFSHORE ASA	Ordinære aksjer	2,000	97,867,000	< 0.01 % directly
R RISØR SHIPPING HOLDING AS	Ordinære aksjer	349,213	51,574,775	< 0.01 % directly
I IDEX BIOMETRICS ASA	Ordinære aksjer	256,000	4,020,000	< 0.01 % directly
R REC SILICON HOLDINGS AS	Ordinære aksjer	0	16,124,000	< 0.01 % directly
E EQVA ASA	Ordinære aksjer	524,648	259,954,753	< 0.01 % directly
N NEXT BIOMETRICS GROUP ASA Under liquidation	Ordinære aksjer	6,616,000	219,899,000	< 0.01 % directly
O ONCOINVENT ASA	Ordinære aksjer	1,909,000	122,658,000	< 0.01 % directly
T THOR MEDICAL ASA	Ordinære aksjer	839,000	475,867,000	< 0.01 % directly
Z ZELLUNA ASA	Ordinære aksjer	6,110,000	300,420,000	< 0.01 % directly
V VESTERÅLEN HAVBRUK AS	Ordinære aksjer	6,507,965	533,058,199	< 0.01 % directly

Limited to direct ownership positions of 0.5% or more.

Last update: Oct 30, 2026